These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35804975)

  • 1. Non-Operative Management of Patients with Rectal Cancer: Lessons Learnt from the OPRA Trial.
    Goffredo P; Quezada-Diaz FF; Garcia-Aguilar J; Smith JJ
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonoperative Management for Rectal Cancer.
    Quezada-Diaz FF; Smith JJ
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):539-551. PubMed ID: 35562257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Nonoperative Management of Rectal Cancer Feasible?
    Quezada-Diaz FF; Smith JJ
    Adv Surg; 2023 Sep; 57(1):141-154. PubMed ID: 37536849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
    Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
    BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 7. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 8. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
    Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
    Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
    [No Abstract]   [Full Text] [Related]  

  • 10. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH).
    Wang Y; Shen L; Wan J; Zhang H; Wu R; Wang J; Wang Y; Xu Y; Cai S; Zhang Z; Xia F
    BMC Cancer; 2022 Mar; 22(1):274. PubMed ID: 35291966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Total Neoadjuvant Therapy Leads to Impressive Response Rates in Rectal Cancer: Results of a German Single-Center Cohort.
    Wurschi GW; Knippen S; Ernst T; Schneider C; Helfritzsch H; Mothes H; Liebe Y; Huber M; Wittig A
    Curr Oncol; 2023 May; 30(6):5366-5378. PubMed ID: 37366890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncological risks associated with the planned watch-and-wait strategy using total neoadjuvant treatment for rectal cancer: A narrative review.
    Socha J; Glynne-Jones R; Bujko K
    Cancer Treat Rev; 2024 Jul; 129():102796. PubMed ID: 38968742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
    Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series.
    Asoglu O; Bulut A; Aliyev V; Piozzi GN; Guven K; Bakır B; Goksel S
    World J Surg Oncol; 2022 Nov; 20(1):358. PubMed ID: 36352416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 16. ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group.
    Fleischmann M; Diefenhardt M; Nicolas AM; Rödel F; Ghadimi M; Hofheinz RD; Greten FR; Rödel C; Fokas E;
    Clin Transl Radiat Oncol; 2022 May; 34():99-106. PubMed ID: 35449546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transition of treatment strategy for locally advanced rectal cancer towards "watch and wait"].
    Xiao WW; Chen G
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):514-520. PubMed ID: 31238631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of total neoadjuvant therapy in locally advanced rectal cancer: a survey of specialists attending the All-Ireland Colorectal Cancer Conference 2022 including lead investigators of OPRA, PRODIGE-23 and RAPIDO.
    O'Brien T; Hospers G; Conroy T; Lenz HJ; Smith JJ; Andrews E; O'Neill B; Leonard G
    Ir J Med Sci; 2024 Jun; 193(3):1183-1190. PubMed ID: 38141097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
    Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
    Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key clinical trials in rectal cancer shaping the current treatment paradigms: reference guide for radiologists.
    Paroder V; Fraum TJ; Nougaret S; Petkovska I; Rauch GM; Kaur H
    Abdom Radiol (NY); 2023 Sep; 48(9):2825-2835. PubMed ID: 37221342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.